Aclaris Therapeutics, Inc. (ACRS) vs Shattuck Labs, Inc. (STTK)

A side-by-side comparison of Aclaris Therapeutics, Inc. and Shattuck Labs, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ACRS vs STTK

growth of $100 · dividends reinvested · last 6y
ACRS +13.9% (+2.2%/yr)STTK -66.4% (-16.6%/yr)ACRS compounded faster over this window
0200400600800Start $100202120222023202420252026$114$34
ACRS STTK

ACRS vs STTK: by the numbers

  • •STTK is the larger company ($530M vs $517M market cap).
  • •Both run net losses; ACRS's is the smaller (-921.50% vs -5256.80% net margin).
  • •ACRS grew revenue faster over the past five years (4.39% vs -11.25% CAGR).

Metrics side by side

Valuation

MetricACRSSTTK
P/S ratio62.87529.58
P/B ratio4.152.51

Profitability

MetricACRSSTTK
Gross margin73.28%-195.10%
Operating margin-975.91%-5150.80%
Net margin-921.50%-5256.80%
ROE-60.79%-24.90%
ROIC-56.99%-26.20%

Growth (annualized)

MetricACRSSTTK
Revenue CAGR (5Y)4.39%-11.25%
Total return CAGR (5Y)-24.23%-20.11%

Frequently asked

Which has grown faster, ACRS or STTK?
Over the past five years, ACRS grew revenue faster — ACRS at a 4.39% CAGR versus STTK at -11.25%.
How have ACRS and STTK total returns compared?
Over the past 5 years, ACRS delivered -24.23% and STTK delivered -20.11% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.